Fusion Biopsy Market Size, Share & Trends Analysis Report By Biopsy Route (Transrectal, Transperineal), By End-use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, And Segment Forecasts, 2023 - 2030

Fusion Biopsy Market Growth & Trends

The global fusion biopsy market size is expected to reach USD 1,115.6 million by 2030, advancing at a CAGR of 8.6% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multipara metric MRI in prostate cancer care are factors expected to drive the market during the forecast period. Moreover, factors such as rising awareness of the value of routine therapeutic interventions and emerging reimbursement policies are projected to drive demand in the market for fusion biopsy.

The high sensitivity and specificity of targeted fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability & reproducibility of the fusion biopsy system in the diagnosis of aggressive tumors is expected to make it a standard tool in prostate biopsy. An increasing number of radiologists gaining expertise in interpreting prostate MRI, coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score, has increased the utilization rate of targeted MR/Ultrasound fusion biopsy systems.

The increasing number of government initiatives in terms of funding research, spreading awareness, and conducting mass screening programs related to prostate cancer are expected to play a crucial in the growth of the market. Some of the growth strategies adopted by market players include partnerships, product launches, participation in trade events and conferences, and acquisitions to drive and sustain growth in this highly competitive space.

Fusion Biopsy Market Report Highlights

The transrectal segment held the largest market share in 2022, as it is the gold standard and commonly used method of prostate fusion biopsy

• The transperineal segment is expected to grow at the fastest rate during the forecast period owing to the safety, diagnostic efficiency, and ability to access ventral prostate areas
• The hospital segment accounted for the largest revenue share in 2022, owing to factors such as the increasing procurement rate of MR/US targeted fusion biopsy systems in teaching hospitals
• The diagnostics centers segment is expected to expand at a significant rate over the forecast period. Shorter wait times, cost efficiency, and developing reimbursement paradigm are the factors expected to drive the growth of this segment
• North America held the largest market share in 2022 and is anticipated to maintain its dominance over the forecast period
• Asia Pacific is anticipated to witness a CAGR of 9.9% during the forecast period, owing to factors such as the growing awareness about the sensitivity and specificity of MRI/US targeted fusion biopsy systems among urologists, especially in countries such as Japan, Australia, and China

Please note The report will be delivered in 2-3 business days upon order notification.